Period-Free Hormone Replacement Therapy

1. Stampfer MJ Colditz GA Willet WC Postmenopausal oestrogen therapy and cardiovascular disease. Ten-year Follow-up from the Nurses' Health Study. New Eng J Med 1991, 325(11): 756–762. 5. Bergkvist L, Adami H-O. Persson I et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. New Eng J Med 1989, 321: 293–297.

2. MacLennan AH . Hormone replacement therapy and the menopause. Med J Aust 1991, 155: 43–44.

3. Coope J Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992, 15: 151–158

4. Brinton LA Hoover R Fruameni JF. Jr Menopausal estrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986, 54: 825–832.

5. Bergkvist L Adami H-O Persson I . The risk of breast cancer after estrogen and estrogen-progestin replacement. New Eng J Med 1989, 321: 293–297.

6. Colditz GA Hankinson SE Hunter DJ Willet WC Manson J-AE Stampfer MJ Hennekens C Rosner B Speizer FE . The use of estrogens and progestogens and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332: 1589–1593.

7. Ferenczy A. Studies on the cytodynamics of human endometrial regeneration. 1 Scanning electron microscopy. Am J Obstet Gynecol 1976a, 124: 64–74.

8. Ferenczy A. Studies on the cytodynamics of human endometrial regeneration. 11 Transmission electron microscopy and histochemistry. Am J Obstet Gynecol 1976b, 124: 582–595.

9. Leather AT Savvas M Studd JWW . Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991, 78: 1008–1010.

10. Okon MA Lee S Li TC . A study to examine women's knowledge, perception and acceptability of HRT. Europ Meno J 1996; 3(2): 47–52.

11. Siseles NO Halperin H Benecia HJ Berg G Pilnik S Mesch V Arrighi B Wikinski RWW . A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas 1995, 21: 201–210.

12. Christiansen C Riis BJ . 17 beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrin & Metab 1990, 71: 836–841.

13. Rymer J Crook D Sidhu M Chapman M Stevenson JC . Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinologica 1993, 128: 259–262.

14. Tang B Markiewicz L Kloosterboer HJ Gurpide E. Human endometrial 3-beta hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestogenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Molec Biol 1993, 45: 345–351.

15. Okon MA Lee S Li TC . The use of androgens in gynaecology. Contemporary Rev Obstet Gynaecol 1996, 8: 25–31.

16. Fentiman IS . Hormone replacement therapy and breast cancer: proceed with caution. J Br Menopause Society, October 1995, 19–21.

17. Kloosterboer HJ Schoonen WGEJ Deckers GH Klijn JGM . Effects of progestogens and Org OD 14 in in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 1994, 49: 311–318.

18. Lindsay R Hart DM Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for prevention of osteoporosis. Br Med J. 1980, 280: 1207–9.

19. Riis BJ Johansen J Christiansen C. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. Maturitas 1988, 10: 51–58.